Form 4 for CORT CORCEPT THERAPEUTICS INC
Accepted 2023-05-11 00:00:00 ET · period of report 2023-05-09 · accession 0000899243-23-012758 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-05-11 | 2023-05-09+ | CORT | Robb Gary Charles | Chief Business Off | S - Sale | $23.93 | -44.0K | 34.0K | -56% | -$1.05M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-10 | S | D | 14,000 | $24.07 | 19,997 | D | — | — | (F2) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $23.99 to $24.16. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. (F3) Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 2 | Common | Common Stock | 2023-05-09 | S | D | 30,000 | $23.87 | 33,997 | D | — | — | (F1) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $23.81 to $24.04. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. (F3) Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |